H. Takahashi

发表

Decreased Warfarin Clearance Associated With the CYP2C9 R150H (*8) Polymorphism

L. Cavallari, S. Patel, Hyunyoung Jeong, 2012, Clinical pharmacology and therapeutics.

Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone

T. Shimizu, H. Echizen, H. Tainaka, 1999, Clinical pharmacology and therapeutics.

A novel microsatellite polymorphism of sodium channel beta1-subunit gene (SCN1B) may underlie abnormal cardiac excitation manifested by coved-type ST-elevation compatible with Brugada syndrome in Japanese.

H. Echizen, N. Matsumoto, F. Miyake, 2010, International journal of clinical pharmacology and therapeutics.

Determination of propranolol enantiomers in human plasma and urine and in rat tissues using chiral stationary-phase liquid chromatography.

H. Ogata, K. Someya, S. Kanno, 1988, Journal of pharmaceutical sciences.

Determination of unbound warfarin enantiomers in human plasma and 7-hydroxywarfarin in human urine by chiral stationary-phase liquid chromatography with ultraviolet or fluorescence and on-line circular dichroism detection.

H. Echizen, H. Takahashi, Y. Shimoyama, 1997, Journal of chromatography. B, Biomedical sciences and applications.

Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children

S. Ishikawa, H. Echizen, S. Nomoto, 2000, Clinical pharmacology and therapeutics.

Longitudinal monitoring of CYP3A activity in patients receiving 3 cycles of itraconazole pulse therapy for onychomycosis

H. Echizen, H. Kubo, S. Shibata, 2014, Journal of clinical pharmacy and therapeutics.

Relative bioavailability of two disopyramide capsules in humans based on total, unbound, and unbound enantiomer concentrations

H. Ogata, H. Takahashi, M. Shimizu, 1993, Biopharmaceutics & drug disposition.

Dosing rate-dependent relationship between propranolol plasma concentration and beta-blockade.

H. Ogata, K. Someya, H. Takahashi, 1993, The Journal of pharmacology and experimental therapeutics.

Comparative pharmacokinetics of unbound disopyramide enantiomers following oral administration of racemic disopyramide in humans.

H. Ogata, K. Masuhara, K. Someya, 1991, Journal of pharmaceutical sciences.

Binding interaction between enantiomers of disopyramide and mono-N-dealkyldisopyramide on plasma protein.

H. Ogata, H. Takahashi, Y. Seki, 1991, Drug metabolism and disposition: the biological fate of chemicals.

Simultaneous determination of disopyramide and its mono-N-dealkylated metabolite enantiomers in human plasma and urine by enantioselective high-performance liquid chromatography.

H. Ogata, K. Masuhara, H. Takahashi, 1990, Journal of chromatography.

Variability in absorption lag time of pyridoxal phosphate under fasting and pre‐ and post‐meal conditions

H. Ogata, H. Takahashi, N. Nagai, 1994, Biopharmaceutics & drug disposition.

Plasma protein binding and blood cell distribution of propranolol enantiomers in rats.

H. Ogata, H. Takahashi, 1990, Biochemical pharmacology.

Plasma protein binding of propranolol enantiomers as a major determinant of their stereoselective tissue distribution in rats.

H. Ogata, S. Kanno, H. Takahashi, 1990, The Journal of pharmacology and experimental therapeutics.

Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes

H. Echizen, H Takahashi, T Kashima, 1998, Clinical pharmacology and therapeutics.

Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes.

T. Shimizu, H. Echizen, S. Nomoto, 1998, Pharmacogenetics.

Decreased absorption as a possible cause for the lower bioavailability of a sustained-release propranolol.

H. Ogata, K. Someya, H. Takahashi, 1990, Journal of pharmaceutical sciences.

Pharmacokinetic interaction between warfarin and a uricosuric agent, bucolome: application of In vitro approaches to predicting In vivo reduction of (S)-warfarin clearance.

H. Echizen, T. Takaba, Harumi Takahashi, 1999, Drug metabolism and disposition: the biological fate of chemicals.

Determination of metoclopramide and its glucuronide and sulphate conjugates in human biological fluids (plasma, urine and bile) by ion-pair high-performance liquid chromatography.

T. Ishizaki, H. Echizen, H. Ogata, 1987, Journal of chromatography.

Developmental changes in the liver weight- and body weight-normalized clearance of theophylline, phenytoin and cyclosporine in children.

H. Echizen, H. Takahashi, M. Kanamori, 2002, International journal of clinical pharmacology and therapeutics.

Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin

H. Echizen, H Takahashi, H Echizen, 2003, The Pharmacogenomics Journal.

Population differences in S-warfarin pharmacokinetics among African Americans, Asians and whites: their influence on pharmacogenetic dosing algorithms

M. Perera, M. T. Lee, M. G. Scordo, 2016, The Pharmacogenomics Journal.

Stereoselective disposition and metabolism of disopyramide in pediatric patients.

K. Chiba, T. Ishizaki, H. Echizen, 1991, The Journal of pharmacology and experimental therapeutics.